{"article_title": "Japan Approves Bristol-Myers Squibb's Hepatitis C Treatment", "article_keywords": ["c", "approves", "treatments", "hepatitis", "approved", "traditional", "treatment", "statement", "japan", "squibbs", "sunvepra", "bristolmyers", "treat"], "article_url": "http://www.wsj.com/articles/japan-approves-bristol-myers-squibbs-hepatitis-c-treatment-1404733185", "article_text": "Japan has approved Bristol-Myers Squibb Co.'s all-oral Daklinza and Sunvepra dual regimen to treat hepatitis C, the company said Monday.\n\nThe combined treatment, which is interferon- and ribavirin-free, is a new option for genotype 1 hepatitis C patients in Japan that haven't been able to take or respond to traditional treatments, the drug maker said in a statement. The treatment was approved by the Japanese Ministry of Health, Labor...", "article_metadata": {"article.template": "snippet", "article.created": "2014-07-07T11:39:00.000Z", "article.section": "Business", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "Japan has approved Bristol-Myers Squibb Co.'s all-oral Daklinza and Sunvepra dual regimen to treat hepatitis C, the company said.", "creator": "@eemccarthy", "image": {"alt": "Japan approves Bristol-Myers Squibb's hepatitis C treatment", "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif"}, "title": "Japan Approves Bristol-Myers Squibb's Hepatitis C Treatment", "site": "@WSJ", "card": "summary"}, "al": {"ios": {"url": "wsj://launch?articleid=SB10001424052702304418604580014820616857884&headline=Japan%20approves%20Bristol-Myers%20Squibb%26apos%3Bs%20hepatitis%20C%20treatment&weburl=http://www.wsj.com/articles/SB10001424052702304418604580014820616857884"}}, "page.site.product": "WSJ", "keywords": "bristol-myers squib,hepatitis c,japan,treatment,Bristol-Myers Squibb,BMY,Japanese Ministry of Health Labor and Welfare,regulation,government policy,new products,services,new product approvals,corporate,industrial news,official trials,tests,political,general news,health,hepatitis,medical conditions,medical treatments,procedures,pharmaceuticals,health care,life sciences", "news_keywords": "bristol-myers squib,hepatitis c,japan,treatment,Bristol-Myers Squibb,BMY,Japanese Ministry of Health Labor and Welfare,regulation,government policy,new products", "article.headline": "Japan approves Bristol-Myers Squibb's hepatitis C treatment", "description": "Japan has approved Bristol-Myers Squibb Co.'s all-oral Daklinza and Sunvepra dual regimen to treat hepatitis C, the company said.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB10001424052702304418604580014820616857884&headline=Japan%20approves%20Bristol-Myers%20Squibb%26apos%3Bs%20hepatitis%20C%20treatment&weburl=http://www.wsj.com/articles/SB10001424052702304418604580014820616857884", "user.type": "nonsubscriber", "article.page": "Business", "page.content.format": "responsive", "article.summary": "Japan has approved Bristol-Myers Squibb Co.'s all-oral Daklinza and Sunvepra dual regimen to treat hepatitis C, the company said.", "page.site": "wsj", "testkeys": "A", "article.published": "2014-07-07T11:39:00.000Z", "dj.asn": "i-f263", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"internal_link_count": 1, "word_count": 217, "publisher": "https://www.facebook.com/wsj"}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "Japan has approved Bristol-Myers Squibb Co.'s all-oral Daklinza and Sunvepra dual regimen to treat hepatitis C, the company said.", "title": "Japan Approves Bristol-Myers Squibb's Hepatitis C Treatment", "url": "http://www.wsj.com/articles/japan-approves-bristol-myers-squibbs-hepatitis-c-treatment-1404733185", "image": {"width": 1200, "identifier": "http://si.wsj.net/img/WSJ_Logo_black_social.gif", "height": 630}, "locale": "en_US", "type": "article"}, "author": "Erin McCarthy", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Japan Approves Bristol-Myers Squibb\u2019s Hepatitis C Treatment", "article.type": "Business", "article.id": "SB10001424052702304418604580014820616857884", "user.exp": "default", "article.updated": "2014-07-07T11:39:00.000Z"}, "_id": "\"57477af36914bd0286fcc038\"", "article_summary": "Japan has approved Bristol-Myers Squibb Co.'s all-oral Daklinza and Sunvepra dual regimen to treat hepatitis C, the company said Monday.\nThe combined treatment, which is interferon- and ribavirin-free, is a new option for genotype 1 hepatitis C patients in Japan that haven't been able to take or respond to traditional treatments, the drug maker said in a statement.\nThe treatment was approved by the Japanese Ministry of Health, Labor..."}